The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. 1965

J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007024 Hypotension, Orthostatic A significant drop in BLOOD PRESSURE after assuming a standing position. Orthostatic hypotension is a finding, and defined as a 20-mm Hg decrease in systolic pressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the person has risen from supine to standing. Symptoms generally include DIZZINESS, blurred vision, and SYNCOPE. Hypotension, Postural,Orthostatic Hypotension,Postural Hypotension
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D010293 Pargyline A monoamine oxidase inhibitor with antihypertensive properties. Pargyline Hydrochloride,Hydrochloride, Pargyline
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006145 Guanethidine An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine,Guanethidine Monosulfate,Guanethidine Sulfate,Guanethidine Sulfate (1:1),Guanethidine Sulfate (1:2),Guanethidine Sulfate (2:1),Guanethidine Sulfate (2:1), 14C-Labeled,Ismelin,Isobarin,Octadine,Oktadin,Monosulfate, Guanethidine,Sulfate, Guanethidine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
June 1966, Prensa medica argentina,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
July 1972, The Journal of pharmacology and experimental therapeutics,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
June 1963, Postgraduate medicine,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
April 1966, Journal of pharmaceutical sciences,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
December 1963, American heart journal,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
August 1980, Canadian Medical Association journal,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
January 1980, British journal of clinical pharmacology,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
June 1977, Journal of medicinal chemistry,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
March 1966, British medical journal,
J A Oates, and A W Seligmann, and M A Clark, and P Rousseau, and R E Lee
January 1988, Archives of internal medicine,
Copied contents to your clipboard!